HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Stoltz, R. Articles by Parisi, S. Search for Related Content PubMed PubMed Citation Articles by Stoltz, R. Articles by Parisi, S. Social Bookmarking                         What's this?

Pharmacokinetic and Safety Evaluation of Palonosetron, a 5-Hydroxytryptamine-3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects

From GFI Pharmaceutical Services, Evansville, Indiana (Dr. Stoltz); Juntendo University School of Medicine, Tokyo, Japan (Dr. Cyong); MGI Pharma, Inc., Bloomington, Minnesota (Dr. Shah); and Helsinn Healthcare SA, Pambio-Noranco, Switzerland (Dr. Parisi).

Palonosetron (Aloxi^TM, Onicit®) is a selective 5-HT₃ receptor antagonist recently approved by the Food and Drug Administration for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. This study was performed to determine the pharmacokinetics and assess the safety and tolerability of intravenous (IV) palonosetron in healthy U.S. and Japanese subjects. Subjects were administered a single IV dose of palonosetron, ranging from 0.3 to 90 µg/kg in either of two randomized, double-blind, placebo-controlled, ascending-dose studies (n = 80 and n = 32, respectively). Serial blood samples were obtained in both studies to evaluate the pharmacokinetics of palonosetron and its N-oxide metabolite, M9. Intravenous palonosetron was well tolerated across a wide range of doses in both studies. The incidence and severity of adverse events (AEs) were similar between subjects receiving palonosetron and those receiving placebo, with no dose-dependent incidences. The most frequently reported AEs were headache, transient elevation of liver enzymes, and constipation. Systemic exposure (AUC and C_max) for palonosetron generally increased with increasing dose. Mean total body clearance, elimination half-life, and apparent volume of distribution ranged from 1.11 to 3.90 mL/min/kg, 33.7 to 54.1 hours, and 3.85 to 12.6 L/kg, respectively, in U.S. subjects and from 2.58 to 3.50 mL/min/kg, 30.8 to 36.8 hours, and 6.96 to 9.85 L/kg, respectively, in Japanese subjects. The pharmacokinetics of palonosetron appeared to be independent of dose, with no dose adjustment required in Japanese subjects. The plasma concentration profile of palonosetron, as represented by a half-life of approximately 40 hours, may provide a clinical advantage over other 5-HT₃ antagonists.

Key Words: 5-HT₃ receptor antagonist • chemotherapy-induced nausea • palonosetron • pharmacokinetics • antiemetic agents

Address for reprints: Simona Parisi, MD, Helsinn Healthcare SA, P.O. Box 357, 6915 Pambio Noranco, Switzerland.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Maemondo, N. Masuda, I. Sekine, K. Kubota, Y. Segawa, M. Shibuya, F. Imamura, N. Katakami, T. Hida, S. Takeo, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann. Onc., November 1, 2009; 20(11): 1860 - 1866. [Abstract] [Full Text] [PDF]

				D. D. Kloth New pharmacologic findings for the treatment of PONV and PDNV Am. J. Health Syst. Pharm., January 1, 2009; 66(1_Supplement_1): S11 - S18. [Abstract] [Full Text] [PDF]

				K. A. Candiotti, A. L. Kovac, T. I. Melson, G. Clerici, T. Joo Gan, and The Palonosetron 04-06 Study Group A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo for Preventing Postoperative Nausea and Vomiting Anesth. Analg., August 1, 2008; 107(2): 445 - 451. [Abstract] [Full Text] [PDF]

				C. Rojas, M. Stathis, A. G. Thomas, E. B. Massuda, J. Alt, J. Zhang, E. Rubenstein, S. Sebastiani, S. Cantoreggi, S. H. Snyder, et al. Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor Anesth. Analg., August 1, 2008; 107(2): 469 - 478. [Abstract] [Full Text] [PDF]

				G. H. Wynn, N. B. Sandson, and K. L. Cozza Gastrointestinal Medications Psychosomatics, February 1, 2007; 48(1): 79 - 85. [Abstract] [Full Text] [PDF]

				M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]

				C. Buoen, O. J. Bjerrum, and M. S. Thomsen How First-Time-in-Human Studies Are Being Performed: A Survey of Phase I Dose-Escalation Trials in Healthy Volunteers Published Between 1995 and 2004 J. Clin. Pharmacol., October 1, 2005; 45(10): 1123 - 1136. [Abstract] [Full Text] [PDF]

				T. L. Hunt, S. C. Gallagher, M. T. Cullen Jr, and A. K. Shah Evaluation of Safety and Pharmacokinetics of Consecutive Multiple-Day Dosing of Palonosetron in Healthy Subjects J. Clin. Pharmacol., May 1, 2005; 45(5): 589 - 596. [Abstract] [Full Text] [PDF]